Company: BDRX
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001214659-25-005742
Chunk: 73

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-11
Form: 20-F
Item: Item 19
Chunk 73
---
2022          
  Research and development                                      8                16                22  
  General and administration                                    5                 5                 5  
                                                               13                21                27  

Key management personnel compensation

Key management personnel are those persons having authority and responsibility for
planning, directing and controlling the activities of the Group, including the Directors of the Company including the Chief Executive
Officer and Chief Scientific Officer.

  Schedule of Management Personnel Compensation                               
  Short term employee benefits                         782      677      668  
  Post-employment benefits                              11       21       21  
  Termination benefits                                  30        –        –  
  Share-based payment                                  201       22       53  
  Management Personnal Compensation                  1,024      720      742  

During the year no Directors (2023:0; 2022: 0) participated in a defined contribution
pension scheme. Pension contributions in the above note include those of the Chief Scientific Officer.

Emoluments disclosed above include the following amounts in respect of
the highest paid Director.

  Schedule of emoluments disclosed                                                               
                                         2024                2023                2022            
  Short term employee benefits                      287                 252                 238  
  Post-employment benefits                          –                   –                   –    
  Management Personnal Compensation                 287                 252                 238  

None of the Directors have exercised share options during the year (2023: nil, 2022:
nil).

6 Finance income and expense

  Schedule of finance income                                                          
  Finance income                                                                      
  Interest received on bank deposits                           166       73       29  
  Other interest receivable                                      1       10        –  
  Gain on equity settled derivative financial liability      3,218      487      468  
  Total finance income                                       3,385      570      497  

                                                  2024                2023               2022           
                                                                                                        
                                                  £’000               £’000              £’000          
 ────────────────────────────────────────────────────────────────────────────────────────────────────────
  Finance expense                                                                                       
  Interest expense on lease liabilities                       19                 28                 43  
  Interest expense on deferred consideration                 144                  –                  –  
  Other loans                                                  2                 13                 10  
  Total finance expense                                      165                 41                 53  

The gain on the equity